Kardiologische Praxis Papenburg
Papenburg, Germany
Cardiologist in Papenburg, Lower Saxony
Hauptkanal Links 100, 26871 Papenburg
About Kardiologische Praxis Papenburg
"Diagnostisches Leistungsspektrum: EKG Belastungs-EKG Langzeit-EKG Langzeit-Blutdruckmessung Abdomensonographie Echokardiographie Transösophageale Echokardiographie Stress-Echokardiographie Duplexsonographie der extrakraniellen Hirngefäße, derExtremitätenarterien und –venen und der retroperitonealen Gefäße (Nierenarterienstenose) Lungenfunktion Intrakranieller Doppler- und Duplexsonographie Schrittmacherkontrollen einschl. biventrikulärer Systeme und ICDs, Ereignisrekorder Kardiorespiratorische Polygraphie Schlafapnoescreening"
- Top Sponsors
- Top Collaborators
- Trials By Phase
- Recruitment Status
- Top Conditions
- Intervention Types
- Top Intervention Names
- Trials By Gender
Lead Sponsor
# Trials
Boehringer Ingelheim
4
Amgen
2
Actelion
1
Milestone Pharmaceuticals Inc.
1
Clinical Trials at Kardiologische Praxis Papenburg
During the past decade, Kardiologische Praxis Papenburg conducted 7 clinical trials. In the 10-year time frame, 7 clinical trials started and 3 clinical trials were completed, i.e. on
average, 42.9% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 3 clinical trials were completed. i.e. 150%
of trials that started reached the finish line.
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
2012-08-22
2019-12-13
Completed
10,471
EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved)
2017-03-02
2021-04-26
Completed
5,988
EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced)
2017-03-06
2020-05-28
Completed
3,730
Efficacy and Safety of Etripamil for the Termination of Spontaneous PSVT. NODE 301 [Part 1 and Part 2 (The RAPID Study)]
2018-06-18
2023-01-20
Completed
701
Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke
2019-06-11
2025-07-26
Active, not recruiting
12,301
Clinical Study to Compare the Efficacy and Safety of Macitentan and Tadalafil Monotherapies With the Corresponding Fixed-dose Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)
2019-07-29
2024-09-24
Active, not recruiting
187
EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction)
2020-12-16
2023-08-31
Active, not recruiting
6,522
A Cross-sectional Study of Lipoprotein(a) Levels in Patients With Documented History of Atherosclerotic Cardiovascular Disease (ASCVD)
2022-04-19
2024-01-05
Recruiting
40,000
Clinical Trials Sponsors and Collaborators
In terms of collaborators to trials, out of the total clinical trials conducted in "Kardiologische Praxis Papenburg"
#1 collaborator was "Eli Lilly and Company" with 3 trials as a collaborator, "IQVIA Biotech" with 1 trials as a collaborator and "Medpace, Inc." with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were
collaborators in the rest 3 trials.
Clinical Trials Conditions at Kardiologische Praxis Papenburg
According to Clinical.Site data, the most researched conditions in "Kardiologische Praxis Papenburg" are
"Heart Failure" (2 trials), "Atherosclerotic Cardiovascular Disease" (1 trials), "Atrial Fibrillation" (1 trials), "Coronary Heart Disease (CHD)" (1 trials) and "Myocardial Infarction" (1 trials). Many other conditions were trialed in "Kardiologische Praxis Papenburg" in a lesser frequency.
Clinical Trials Intervention Types at Kardiologische Praxis Papenburg
Most popular intervention types in "Kardiologische Praxis Papenburg" are "Drug" (6 trials) and "Other" (1 trials). Other intervention types were less common.
The name of intervention was led by "Placebo" (5 trials), "Empagliflozin" (3 trials), "Etripamil" (1 trials), "Evolocumab" (1 trials) and "FDC macitentan/tadalafil" (1 trials). Other intervention names were less common.
Clinical Trials Genders at Kardiologische Praxis Papenburg
The vast majority of trials in "Kardiologische Praxis Papenburg" are
8 trials for "All" genders.
Clinical Trials Status at Kardiologische Praxis Papenburg
Currently, there are NaN active trials in "Kardiologische Praxis Papenburg".
undefined are not yet recruiting,
1 are recruiting,
3 are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were 4 completed trials in Kardiologische Praxis Papenburg,
undefined suspended trials,
and undefined terminated clinical trials to date.
Out of the total trials that were conducted in Kardiologische Praxis Papenburg, 0 "Phase 1"
clinical trials were conducted, 0 "Phase 2" clinical
trials and 6 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 0 trials, and there were
also 1 trials that are defined as “Not Applicable".